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Abstract
Herpes simplex virus type 1 (HSV-1) virions contain a proteinaceous layer termed the tegument that lies between the nucleocapsid and viral
envelope. The mechanisms underlying tegumentation remain largely undefined for all herpesviruses. Using glutathione S-transferase (GST)
pulldowns and coimmunoprecipitation studies, we have identified a domain of the tegument protein VP22 that facilitates interaction with VP16.
This region of VP22 (residues 165–225) overlaps the glycoprotein E (gE) binding domain of VP22 (residues 165–270), which is sufficient to
mediate VP22 packaging into assembling virus particles. To ascertain the contribution of the VP16 and gE binding activities of VP22 to its virion
incorporation, a transfection/infection based virion incorporation assay, using point mutants that discern between the two binding activities, was
utilized. Our results suggest that interaction with VP16 is not required for incorporation of VP22 into virus particles and that binding to the
cytoplasmic tail of gE is sufficient to facilitate packaging.
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Herpesviruses share common virion morphology; icosahe-
dral capsids containing the viral genome are surrounded by an
amorphous layer of at least 20 proteins known as the tegument,
which is in turn enclosed by a lipid bilayer composed of 11 or
more virally encoded glycoproteins (Roizman and Sears, 2001).
While it is well established that capsid assembly and packaging
of the viral genome occur in the nucleus, the compartment(s) in
which the tegument and envelope are acquired is less well-
defined (Enquist et al., 1998; Mettenleiter, 2000, 2002). As with
other herpesviruses, the current model for herpes simplex virus
type 1 (HSV-1) assembly and egress suggests that nucleocapsids
are shuttled to the cytoplasm via a budding/fusion event that
occurs across the inner and outer membranes of the nucleus,
respectively. The unenveloped nucleocapsids then travel
through the cytoplasm until they reach a trans-Golgi network
(TGN)-derived vesicle. While at this site, nucleocapsids are⁎ Corresponding author. Fax: +1 717 531 6522.
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that also results in the acquisition of tegument and viral
glycoproteins (Gershon et al., 1994; Granzow et al., 1997,
2001; Harley et al., 2001; Mettenleiter, 2002, 2004; Sanchez et
al., 2000; Skepper et al., 2001; Van Genderen et al., 1994;
Whealy et al., 1991; Whiteley et al., 1999; Zhu et al., 1995). The
mature virions subsequently follow the secretory pathway to the
cell surface, where they are released into the extracellular milieu
(Mettenleiter, 2002).
In contrast to nucleocapsid assembly, the molecular mechan-
isms of tegumentation and the process of final envelopment are
poorly understood (Mettenleiter, 2002, 2004; Roizman and
Sears, 2001). Tegumentation of nucleocapsids can theoretically
occur at various stages in the egress pathway: in the nucleus, at
the nuclear membrane, in the cytoplasm or during budding at the
TGN. Recent studies have demonstrated that a subset of the
tegument proteins are added to the capsid prior to nuclear egress;
however, the mechanism behind the addition of the majority of
the tegument components remains elusive (Bucks et al., 2007;
Naldinho-Souto et al., 2006). Understanding how the process of
tegumentation occurs is important as evidence indicates that
tegument proteins, possibly in concert with certain viral
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at the TGN (McLauchlan and Rixon, 1992; Rixon et al., 1992;
Szilagyi and Cunningham, 1991). Our studies have focused on
defining the protein–protein interactions of one specific HSV-1
tegument protein, VP22, and the role these interactions play in
facilitating the incorporation of VP22 into assembling virions.
Encoded by the UL49 gene of HSV-1, VP22 is a highly
phosphorylated, 301-amino-acid protein which is one of the
most abundant tegument components, with an estimated 2000
copies of the protein packaged per virion (Elliott and Meredith,
1992; Heine et al., 1974; Leslie et al., 1996). Despite its
abundance, the role of VP22 during HSV-1 assembly and the
mechanism of its incorporation, remain undefined.
VP22 interacts with VP16, another abundant tegument
protein, which is essential for secondary envelopment and egress
(Elliott et al., 1995, 2005; Mossman et al., 2000; Weinheimer et
al., 1992). Transmission immunoelectron microscopy (TIEM)
studies suggest that during viral assembly, detectable amounts of
VP16 are added to the capsid in the nucleus, with additional
VP16 added as the nucleocapsid moves through the cytoplasm,
prior to final envelopment (Miranda-Saksena et al., 2002;
Naldinho-Souto et al., 2006). In contrast, VP22 is packaged
into virions during final envelopment as nucleocapsids bud into
TGN-derived vesicles (Miranda-Saksena et al., 2002). Consistent
with this observation, previous studies have shown that VP22
associates with membranes and localizes to acidic compartments
of the cell including the TGN (Brignati et al., 2003).
Although little is known about the molecular details of final
tegumentation and envelopment, it is likely that protein–protein
interactions between tegument proteins or between tegument
proteins and the cytoplasmic tails of virally encoded glycopro-
teins, facilitate the process and may result in the incorporation of
viral proteins into the assembling particle. TwoVP22 null viruses
have recently been described and demonstrate a variety of cell-
specific replication defects with altered virion composition
including decreased packaging of both glycoprotein D (gD) and
glycoprotein E (gE) (Duffy et al., 2006; Elliott et al., 2005;
Pomeranz and Blaho, 2000). VP22 binds to the cytoplasmic tails
of both gD and gE, and may facilitate the interaction of viral
nucleocapsids with glycoproteins lining up on the membranes of
TGN-derived vesicles, perhaps through its interactionwithVP16
(Chi et al., 2005; O'Regan et al., 2006). In HSV-1, simultaneous
deletion of gD and gE results in accumulation of unenveloped
capsids in the cytoplasm that are embedded in tegument-like
material, a similar phenotype to that seen with a VP16 null virus
(Farnsworth et al., 2003; Mossman et al., 2000; Weinheimer et
al., 1992). In pseudorabies virus (PrV) the cytoplasmic tails of
the envelope glycoproteins gE and gM bind to VP22 in a yeast
two-hybrid study (Fuchs et al., 2002). Interestingly, simulta-
neous deletion of gM and the gE/gI heterodimer results in
reduced amounts of VP22 in the mature PrV particle, and in the
formation of capsid-bound tegument aggregates in the cytoplasm
(Brack et al., 1999, 2000; Fuchs et al., 2002). Furthermore, the
Bartha stain of PrV,which lacks the glycoproteins gI and gE, fails
to package VP22 (Lyman et al., 2003).
Previous studies from our laboratory demonstrated that the
gE binding domain of VP22 (residues 165–270) competes effi-ciently with wild-type VP22 for packaging into assembling virus
particles (O'Regan et al., 2006). Interestingly, a recent study
suggested that a similar domain of VP22 may facilitate binding
to VP16, and reported a correlation between the ability of VP22
to bind VP16 and its incorporation into virus particles (Hafezi et
al., 2005). The focus of the current study was to elucidate the role
these protein–protein interactions play in the virion packaging of
VP22.
Deletion mutagenesis was used to identify the minimal
domain of VP22 that is required for interaction with VP16. The
experiments presented in this report extend the findings of
Hafezi et al. (2005) and reveal a central region that is both
necessary and sufficient to facilitate interaction with VP16.
Membrane flotation experiments suggest that this region of
VP22 tagged with the green fluorescent protein (GFP), has the
ability to associate with cellular membranes; however, this
activity is not sufficient to facilitate virion incorporation of VP22
and additional protein–protein interactions appear to be
required. Using site-directed point mutagenesis to discern
between the VP16 and gE binding activities of VP22, virion
incorporation studies suggest that VP16 binding is not a
requirement for incorporation of VP22 into assembling virus
particles. This report extends our knowledge of the network of
protein–protein interactions that facilitates the process of final
tegumentation and envelopment and further defines the
mechanism by which VP22 is incorporated into virus particles.
Results
Mapping the domain of VP22 that facilitates interaction with
VP16
To ascertain the domain of VP22 that facilitates interaction
with VP16, a series of N-terminal and C-terminal truncation
mutants was made in the context of a GST-VP22 fusion protein
(Fig. 1A). All deletions were designed to avoid major disrup-
tions in protein folding that could result from truncating the
protein in the middle of a hydrophobic region. The truncation
mutants were evaluated in a glutathione S-transferase (GST)
pulldown assay for their ability to bind to VP16. HSV-1-
infected cell lysates were incubated with equivalent amounts of
purified GST fusion proteins bound to glutathione-Sepharose
beads. After a 3-h incubation, beads were washed extensively
with lysis buffer, and bound material was separated by sodium
dodecyl sulfate (SDS)–10% polyacrylamide gel electrophor-
esis (PAGE) and then analyzed on Western blots. Unlike GST
alone, the GST-VP22 fusion protein reacted with a 65 kDa
protein that was recognized by the anti-VP16 antiserum
(Fig. 1B). Upon deletion of the N-terminal 43, 86, 120 or
even 164 amino acids of VP22, VP16 binding was still
detectable; however VP22.87-301 bound to VP16 weakly, a
reproducible observation that may suggest problems in protein
folding with this truncation mutant. However, when the N-
terminal 225 or 270 residues of VP22 were deleted, binding
was abolished. These results indicate that the region of VP22
that facilitates interaction with VP16 lies within the C-terminal
137 amino acids.
Fig. 1. Characterization of the ability ofVP22 truncationmutants to bindVP16 in aGSTpulldown assay. (A)N-terminal andC-terminal truncations ofVP22 fused toGST.
A schematic representation of full length, N-terminal and C-terminal truncated forms of VP22 fused to the C-terminus of the GST protein. (B and C) GST pulldown from
HSV-1-infected cell lysates usingGST–VP22 andN-terminal andC-terminal truncationmutants respectively. TheGST fusion proteinswere expressed inEscherichia coli
cells, purified on glutathione-Sepharose beads, and approximately equal amounts of each were added to NP-40 lysates of Vero cells that had been infected with HSV-1.
Beads were washed extensively with lysis buffer and bound proteins were separated by SDS-PAGE and transferred to nitrocellulose. Western blot analysis was performed
using a rabbit monospecific polyclonal antibody raised against VP16. (D) VP16 interaction domain mutants of VP22 fused to GST. Schematic representation of VP22,
deletion of amino acids 87–120 of VP22 or the predicted VP16 interaction domain of VP22, and the interaction domain alone fused to the C-terminus of the GST protein.
(E) GST pulldown from HSV-1-infected cell lysates using VP16 interaction domain mutants of VP22. Purified fusion proteins were tested for their ability to bind VP16
from HSV-1 infected cells, as described in the legend to panels B and C. The positions of molecular mass markers (in kilodaltons) are indicated on the left.
265K.J. O'Regan et al. / Virology 369 (2007) 263–280To further map the VP16 interaction domain of VP22, we
also characterized the ability of the C-terminal truncation
mutants to bind VP16 from HSV-1-infected cell lysates (Fig.
1C). The first 43, 86, 120 or 164 amino acids of VP22 were not
sufficient to facilitate binding of VP22 to VP16; however,
constructs containing the first 225 or 270 residues were able to
bind. Collectively, these experiments indicate that amino acids
165–225 of VP22 facilitate the interaction with VP16.
Residues 165–225 of VP22 are sufficient to pulldown VP16
To examine whether residues 165–225 of VP22 are sufficient
to facilitate interaction with VP16, this segment of VP22 was
fused to the C-terminus of GST. In addition, a GST-VP22
construct was made in which these amino acids are absent (Fig.
1D). Both mutants were evaluated for their ability to interact with
VP16 from HSV-1-infected cell lysates. As predicted, VP16failed to bind to the fusion protein in which amino acids 165–
225 were deleted (VP22.Δ165–225) (Fig. 1E). Binding was
detected when amino acids 87–120 were deleted (Fig. 1E),
indicating that the VP22–VP16 interaction is not sensitive to all
internal deletions. Furthermore, amino acids 165–225, when
fused to GST, were sufficient to pulldown VP16 from infected-
cell lysates (Fig. 1E), although not to the level of wild-type
VP22. These data suggest that amino acids 165–225 of VP22
comprise a minimal domain of the protein that is both
necessary and sufficient to facilitate its interaction with VP16.
Coimmunoprecipitation of GFP-tagged VP22 truncation
mutants with VP16
Immunoprecipitation assays from transfected/infected cell
lysates were performed to ascertain if a similar interaction of
VP22 and VP16 occurred within the context of an infected cell.
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tagged with GFP creating the fusion proteins represented in Fig.
2A. Vero cells were transfected with GFP alone or the various
truncated forms of VP22 fused to GFP. At 20 h post-transfection,
cells were infected with HSV-1 at a MOI of 10. After an
additional period of 10 h, the infected cells were lysed with NP-
40 lysis buffer. A fraction of each cell lysate was analyzed by
Western blotting to verify that the GFP-tagged truncation
mutants were expressed in the transfected/infected cells (Figs.
2B and D). The remaining lysates were then incubated with goat
anti-GFP antibodies followed by protein G-agarose beads. The
immunoprecipitated material was separated by SDS-PAGE and
analyzed by Western blotting using rabbit anti-VP16 antibodies
to assay for the immunoprecipitation of VP16 with the VP22Fig. 2. Coimmunoprecipitation of N-terminal and C-terminal VP22 truncation mutant
GFP. A schematic representation of full length, N-terminal and C-terminal truncated f
of VP22 N-terminal and C-terminal truncation mutants respectively, in transfecte
transfected cells (Mock) were infected with HSV-1, and at 10 h post-infection were
Western blotting using a goat polyclonal antibody specific for GFP. (C and E) Coimm
VP22, respectively. The remainder of the transfected/infected cell lysate was incub
antigen complexes were collected with protein G-agarose beads. After extensive wa
was separated by SDS-PAGE and transferred to nitrocellulose. Coimmunoprecipita
antibody raised against a C-terminal peptide of VP16. The positions of molecular mtruncation mutants. When the N-terminal truncations were
analyzed for their ability to interact with VP16 within the
transfected/infected cell, results similar to those found with the
GST pulldown assay were observed. Deletion of the first 43, 86,
120 or 164 amino acids had no effect on the ability of VP16 to
coimmunoprecipitate with VP22 (Fig. 2C), whereas deletion of
the N-terminal 225 or 270 residues of VP22 abrogated VP16
binding. Thus, these results confirm that the region of VP22
required to facilitate interaction with VP16 resides within the C-
terminal 137 amino acids.
Analysis of the C-terminal truncations of VP22 showed that
restoration of the N-terminal 43, 86, 120 or 164 amino acids of
VP22 was not sufficient to promote the interaction of VP22 and
VP16 when assayed by coimmunoprecipitation from trans-s with VP16. (A) N-terminal and C-terminal truncation mutants of VP22 fused to
orms of VP22 fused to the N-terminus of the GFP protein. (B and D) Expression
d/infected cells. Vero cells expressing GFP, VP22–GFP constructs or mock
lysed with NP-40 lysis buffer. A fraction of each cell lysate was analyzed by
unoprecipitation of VP16 with N-terminal and C-terminal truncation mutants of
ated with a goat polyclonal antibody against GFP and the resulting antibody–
shes with lysis buffer, material that immunoprecipitated with anti-GFP antibody
ted VP16 was detected by immunoblot using a rabbit monospecific polyclonal
ass markers (in kilodaltons) are indicated on the left.
Fig. 3. Immunoprecipitation-Western analysis of the VP22 domain that facilitates
interaction with VP16. (A) VP16 interaction domain mutants of VP22 fused to
GFP. Schematic representation of VP22, deletion of the VP16 interaction domain
of VP22 (as indicated by immunoprecipitation-Western), and the interaction
domain alone fused to the N-terminus of the GFP protein. Also represented,
deletion of theVP16 interaction domain ofVP22 (as indicated byGSTpulldown),
and this interaction domain alone fused to GFP. Expression of VP22 truncation
mutants in transfected/infected cells (B) and their ability to coimmunoprecipitate
with VP16 (C) were analyzed as described in the legend to Fig. 2.
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GST pulldown assay, restoration of the first 225 amino acids did
not allow VP16 to bind VP22 in transfected/infected cells (Fig.
2E). The variance seen between the results of the two assays may
be attributable to the location of the protein fusion. The GFP tag
fused to the C-terminus of the VP22 truncation mutant may
contribute some steric hindrance, which affects the interaction
between VP22.1–225 and VP16. VP16 did coimmunoprecipi-
tate with VP22.1–270 in which the first 270 amino acids of
VP22 are fused to GFP (Fig. 2E). Collectively, the immunopre-
cipitation assay in transfected/infected cells suggests that amino
acids 165–270 of VP22 facilitate its interaction with VP16.
To clarify whether residues 165–225 or 165–270 are indeed
sufficient to facilitate interaction with VP16, these two peptides
and VP22-derivatives lacking each of these segments were fused
to GFP for analysis in the coimmunoprecipitation assay (Fig.
3A). Western blot analysis with anti-GFP antibodies indicated
that the VP22 interaction domain mutants were expressed in the
transfected/infected cells and migrated with the expected
molecular masses (Fig. 3B). Analysis of the mutants for their
ability to interact with VP16 by the immunoprecipitation-
Western assay demonstrated that upon deletion of either domain
(165–225 or 165–270) from VP22, VP16 failed to coimmuno-
precipitate (Fig. 3C). In contrast, amino acids 165–270 fused to
GFP did coimmunoprecipitate VP16 at levels similar to wild-
type VP22. When amino acids 165–225 of VP22 fused to GFP
were expressed in the transfected/infected cell system, VP16
was reproducibly detected, although at reduced levels when
compared to the wild-type VP22 construct or the VP22.165–270
GFP fusion protein. Overall, these findings suggest that residues
165–225 of VP22, whether fused to GST or GFP, are unable to
facilitate optimal binding with VP16 as compared to the wild-
type VP22 construct.
The VP16 interaction domain of VP22 can bind to VP16 in the
absence of additional viral proteins
The GST pulldown experiments and coimmunoprecipitation
studies were performed with infected cell lysates and trans-
fected/infected cell lysates respectively. Thus, in addition to our
mutant constructs, virally encoded wild-type VP22 is present in
both experimental systems. Recent studies have suggested that
VP22 may possess the ability to multimerize (Mouzakitis et al.,
2005; Vittone et al., 2005). Therefore the wild-type VP22 could
theoretically act as a bridge between VP16 and the VP22
truncation mutants under study. To confirm that we have indeed
identified the minimal domain of VP22 that is responsible for its
interaction with VP16, we examined the interaction in the
absence of infection. Vero cells were transfected with GFP alone
or the various mutants of the VP16 interaction domain of VP22.
At 20 h post-transfection, cells were lysed with NP-40 lysis
buffer and a fraction of each cell lysate was analyzed byWestern
blotting to verify that the GFP-tagged constructs were expressed
(Fig. 4A). The remaining lysates were then incubated with either
GSTor GST-VP16 bound to glutathione-Sepharose beads. After
a 3-h incubation, beads were washed extensively with lysis
buffer, and bound material was separated by SDS-PAGE andthen analyzed by Western blotting. VP22 fused to GFP was
efficiently pulled-down from the transfected cell lysates,
indicating that the interaction can occur in the absence of
additional viral proteins (Figs. 4B and C). Deletion of either
domain (165–225 or 165–270) from VP22 reduced binding to
GST-VP16 to background levels. However, when residues 165–
270 of VP22 were assayed in this system, this region bound to
GST–VP16 at enhanced levels (Figs. 4B and C). In contrast,
residues 165–225 although capable of binding to VP16, did so at
reduced levels (approximately 30% of wild-type VP22).
Collectively, these results suggest that residues 165–225 of
VP22 are sufficient to facilitate binding to VP16 in the absence
of additional viral encoded proteins, however in order to attain
Fig. 4. Analysis of the VP22 domain that facilitates interaction with VP16 in a GST pulldown assay. (A) Expression of the VP22 truncation mutants represented in Fig.
3A, in transfected cells. Vero cells were transfected with the indicated constructs. At 20 h post-transfection, the transfected monolayers were lysed with NP-40 lysis
buffer. A fraction of each cell lysate was analyzed for expression of the VP22-GFP fusion proteins by Western blotting using a rabbit polyclonal antibody specific for
GFP. (B) GST pulldown from transfected cell lysates using GST–VP16. The GST fusion proteins were expressed in Escherichia coli cells, purified on glutathione-
Sepharose beads, and approximately equal amounts of each were added to the remainder of the transfected cell lysates. Beads were washed extensively with lysis
buffer and bound proteins were separated by SDS-PAGE and transferred to nitrocellulose. Western blot analysis was performed using a rabbit polyclonal antibody
raised against the GFP protein. The positions of molecular mass markers (in kilodaltons) are indicated on the left. (C) Binding efficiency of VP22 truncation mutants to
VP16. Using densitometry, binding efficiency was quantitated by dividing the amount of VP22–GFP protein detected in the pulldown assay (normalized for the
amount of GST–VP16 present) by the amount in the cell lysate (normalized for the amount of actin present). In each experiment, the wild-type VP22–GFP construct
was set at 100% binding efficiency. Error bars represent standard deviations for four replicate experiments.
268 K.J. O'Regan et al. / Virology 369 (2007) 263–280wild-type levels of binding, residues 165–270 of VP22 (which
are also sufficient to facilitate binding to the cytoplasmic tail of
gE; O'Regan et al., 2006) are required.
Membrane association of the VP16 interaction domain of
VP22
VP22 is known to partition with the cellular membrane
fraction in the absence of additional HSV-1 proteins (Brignati et
al., 2003). We were curious to study if the membrane association
activity mapped to the same region of VP22 that facilitates
VP16 and gE binding, and whether membrane association is
sufficient to facilitate virion incorporation or if additional
protein–protein interactions are required. To examine the
membrane association of the interaction domains of VP22 we
utilized a membrane flotation assay. Vero cells were transfected
with GFP alone or the various mutants of the VP16 interaction
domain of VP22. At 24 h post-transfection, the monolayerswere harvested and resuspended in hypotonic buffer. After
mechanical lysis and clarification, the resulting supernatants
were added to 85% (wt/vol) sucrose to yield a final sucrose
concentration of 72%. A discontinuous gradient was formed by
overlaying this mixture with 65% and 10% sucrose. Due to the
buoyant density of membranes, ultracentrifugation results in
flotation of membrane-associated proteins to the interface
between the 65% and 10% sucrose layers. Twelve fractions
were collected from the bottom of the tube and the proteins were
separated by SDS-PAGE and analyzed byWestern blotting. GFP
failed to associate with membranes in this assay and was found
predominantly in fractions 1 through 3 where one would expect
non-membrane associated proteins to migrate (Fig. 5). In
contrast, VP22-GFP was detected in fractions 10 and 11
(corresponding to the 65–10% interface) where membrane
associated proteins are found (Fig. 5). Deletion of either domain
(165–225 or 165–270) from VP22 abrogated membrane
association with both mutant proteins detected solely in fractions
Fig. 5. Membrane flotation of the VP22 domains that facilitate interaction with
VP16 and gE. Vero cells were transfected with the VP22 mutants represented in
Fig. 3A. At 24 h post-transfection, the transfected monolayers were scraped into
PBS, washed and resuspended in hypotonic buffer. Swollen cells were disrupted
by passage through a 25 gauge needle and nuclei were removed by low-speed
centrifugation. The resulting supernatants were added to 85% (wt/vol) sucrose in
NTE buffer to yield a final sucrose concentration of 72%. A discontinuous
gradient was formed by overlaying this mixture with 65% sucrose followed by
10% sucrose. After centrifugation at 100,000×g for 18 h at 4 °C in a Beckman
SW41 rotor, 12 fractions were collected from the bottom of the tube. After TCA
precipitation of each fraction, proteins were separated by SDS-PAGE and
transferred to nitrocellulose. GFP-tagged proteins were detected by Western
blotting using a goat polyclonal antibody raised against the GFP protein.
Fractions 1–3 contain non-membrane associated proteins while fractions 10 and
11 correspond to the 65–10% sucrose interface and contain cellular membranes.
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assayed in this system, this region associated with membranes at
levels similar to that seen with the full-length construct (Fig. 5).
Interestingly, when VP22.165–225 was examined in the
flotation assay it exhibited a higher level of membrane
association when compared to the wild-type VP22 construct
(compare protein levels in fraction 10 versus fraction 1 through
3, Fig. 5). Collectively, these results suggest that the membrane
association activity of VP22 does overlap with both the VP16
and gE binding domains of VP22, with the highest level of
membrane association observed with residues 165–225 of
VP22, which are unable to bind to gE and facilitate only
moderate levels of VP16 binding (30% of wild-type VP22).
Role of VP16 binding and membrane association in the
packaging of VP22 into assembling virions
Recent studies have reported a correlation between the
incorporation of VP22 into virus particles and VP16 binding
(Hafezi et al., 2005). Thus, it was of interest to ascertain whether
the domain of VP22 that facilitates interaction with VP16 was
packaged into assembling virus particles. To examine this
possibility, we utilized a transfection/infection-based packaging
assay. Vero cells were transfected with plasmids encoding
various VP22-GFP fusion proteins and subsequently infected
with either wild-type HSV-1 (data not shown), or a VP22-null
virus (UL49
−) to eliminate any contribution that VP22 multi-
merization may play in the incorporation of the VP22 truncation
mutants under study. At 18 h post-infection, extracellular
virions were harvested and then pelleted through a sucrosecushion. The pelleted virions were analyzed byWestern blotting
using GFP-specific antisera to detect the VP22–GFP fusion
proteins. To confirm that approximately equal amounts of virus
were loaded with each sample, Western blots were stripped and
reprobed for the major capsid protein VP5.
Analysis of the expression of the various VP22–GFP
constructs within the transfected/infected cells showed that each
was expressed and migrated at the expected molecular weight
(Fig. 6A). With regard to packaging, wild-type VP22–GFP was
incorporated into virus particles, whereas GFP alone was virtually
undetectable, despite high expression in the transfected/infected
cells, indicating that GFP itself does not have a significant effect
on packaging (Figs. 6B and C). Furthermore, none of the VP22–
GFPmutant proteins were detected in the media from transfected/
mock-infected cells, and many transfected constructs failed to be
packaged upon infection indicating that incorporation is in fact a
specific event and not due to aggregates that can pellet through
the sucrose cushion (Fig. 6 and data not shown). We found that
deletion of residues 165–225 of VP22 reduced packaging to
background levels, however upon deletion of the 165–270 VP16
interaction domain, the resulting mutant was packaged at
extremely low (approximately 8% of wild-type VP22) but
reproducible levels (Figs. 6B and C). A VP22 virion packaging
signal has been described in the C-terminus of VP22 which may
facilitate gD binding (personal communication from Dr. John
Blaho, Mount Sinai School of Medicine, New York). This signal
is contained in VP22.Δ165–270 and may account for the low
levels of incorporation seen with this mutant. Curiously,
VP22.Δ165–225, which also contains the putative virion
packaging signal, failed to be packaged at similar levels to
VP22.Δ165–270, an observation that may be attributable to
differential folding between the two mutants.
VP22.165–225, which binds to VP16 albeit at reduced levels
compared to wild-type VP22 and associates with cellular
membranes, failed to be packaged into virions at detectable
levels. However, residues 165–270 of VP22, which are
sufficient for optimal binding to VP16 and also associate with
cellular membranes and bind to the cytoplasmic tail of gE, did
facilitate virion incorporation to levels approaching 54% of the
wild-type VP22–GFP construct (Figs. 6B and C). Interestingly,
when these experiments were repeated with wild-type HSV-1
rather that a VP22-null virus, despite the mutant constructs
differential binding to wild-type VP22 (data not shown), the
relative levels of incorporation remained the same, indicating
that full-length VP22 does not facilitate the incorporation of the
truncated VP22 constructs into the virus particle (data not
shown). These results suggest that the ability to associate with
cellular membranes is not sufficient to facilitate virion
incorporation and that additional protein–protein interactions
(VP16 binding, at least to wild-type levels, and gE binding but
not VP22 multimerization) may be an important determinant for
the incorporation of VP22 into virions.
VP22 dileucine motif mutants fail to bind to VP16
Previous studies from our laboratory demonstrated that the
gE binding domain of VP22 also maps to residues 165–270
Fig. 6. Virion incorporation of the VP22 domain that facilitates interaction with VP16. Vero cells were transfected with the indicated VP22–GFP constructs, and 20 h
later, they were infected with a VP22-null virus (UL49
−). After an additional 20-h incubation, cell lysates were prepared (A) and virions were collected from the media
by centrifugation through a 30% sucrose cushion (B). Cell lysates and extracellular virus were separated by SDS-PAGE and transferred to nitrocellulose. Western blot
analysis was performed using a rabbit polyclonal antibody specific for GFP. As a loading control, the blot was stripped and reprobed with a rabbit polyclonal antibody
raised against the HSV-1 major capsid protein VP5. The positions of molecular mass markers (in kilodaltons) are indicated on the left. (C) Packaging efficiency. Using
densitometry, packaging efficiency was quantitated by dividing the amount of VP22–GFP protein detected in extracellular virus particles (normalized for VP5) by the
amount in the cell lysate (normalized for VP5). In each experiment, the wild-type VP22–GFP construct was set at 100% packaging efficiency. Error bars represent
standard deviations for four replicate experiments.
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unable to bind to the cytoplasmic tail of gE (data not shown),
failed to be packaged into assembling virus particles despite their
ability to bind to VP16. Thus, conceivably both binding
activities may be required to facilitate VP22's incorporation.
In an attempt to identify and possibly separate the two
discrete activities contained within this domain, and to define the
contribution of VP16 and gE binding to VP22's incorporation, a
series of N-terminal and C-terminal truncations of the 165–270
domain of VP22 were created. When the truncation mutants
were evaluated for their ability to bind to the cytoplasmic tail of
gE in a GST pulldown assay, even the smallest truncation abro-
gated binding (data not shown).Primary structural alignment reveals that residues 165–270
of HSV-1 VP22 are highly conserved among VP22 homo-
logues of herpesviruses (Fig. 7A). In a further attempt to
uncouple the two binding activities, a more subtle approach
of targeting conserved residues for site-directed point
mutagenesis was utilized. Two conserved “dileucine motifs”
were the initial targets for mutagenesis. These residues were
chosen because dileucine motifs function as binding sites for
a variety of proteins (Heilker et al., 1999; Loomis et al.,
2003). The residues in question were mutated to alanines in
the context of full length VP22 fused to the N-terminus of
GFP, creating the constructs LL (−), LI (−) and LL (−)/LI (−)
(Fig. 7B).
Fig. 7. Analysis of the VP22 sequence. (A) Sequence alignment of VP22 homologs. The alignment of alphaherpesvirus VP22 homologs is shown, which includes that
of herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), pseudorabies virus (PRV), bovine herpesvirus-1 (BHV-1), equine herpesvirus-4 (EHV-
4), varicella-zoster virus-Dumas (VZV-D), and Marek's disease virus-Georgia (MDV-GA). Blue text indicates identity and green text denotes similarity. The
conserved “dileucine” motifs are boxed. (B) Dileucine motif mutants of VP22 fused to GFP. Schematic representation of wild-type VP22, and VP22 amino acid
substitution mutants used in this study, fused to the N-terminus of the GFP protein. (C) Localization of VP22 dileucine motif mutants. Vero cells were transfected with
the indicated VP22–GFP constructs, and 20 h later, they were infected with HSV-1. At 18 h post-infection (38 h post-transfection), cells were fixed with
paraformaldehyde and examined by confocal microscopy with the appropriate wavelength to excite GFP and DAPI.
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to VP16 in both the presence and absence of infection using the
previously described coimmunoprecipitation assay and GST–
VP16 pulldown assay, respectively. Initial localization studies
demonstrated that the dileucine motif mutants display a
subcellular localization reminiscent of wild-type VP22 in the
transfected/infected cells (Fig. 7C), suggesting that the failure of
any of the mutants to bind VP16/gE or to be incorporated into
the virus particle is not due to a gross mislocalization within the
cell.
Analysis of the expression of the various dileucine motif
mutants within the transfected/infected (Fig. 8A) and trans-fected only cells (Fig. 8C) showed that each was expressed at
levels similar to wild-type VP22, and migrated at the expected
molecular weight. With regards to VP16 binding, VP16
coimmunoprecipitated efficiently with the wild-type VP22
construct, but mutation of either of the dileucine motifs found
in VP22 abrogated binding (Fig. 8B). A similar result was
observed in the absence of infection; VP22 fused to GFP was
efficiently pulled-down from the transfected cell lysates,
whereas LL (−), LI (−) or LL (−)/LI (−) failed to bind to
GST–VP16 (Figs. 8D and E). These results suggest that
mutation of either of the VP22 dileucine motifs to alanine
residues disrupts the interaction of VP22 and VP16.
Fig. 8. Characterization of the ability of VP22 dileucine motif mutants to bind VP16. Expression of VP22 dileucine motif mutants in transfected/infected cells (A) and
their ability to coimmunoprecipitate with VP16 (B) were analyzed as described in the legend to Fig. 2. Expression of VP22 dileucine motif mutants in transfected cells
(C), their ability to bind to GST–VP16 (D) and the binding efficiency (E) were analyzed as described in the legend to Fig. 4. The positions of molecular mass markers
(in kilodaltons) are indicated on the left. Error bars represent standard deviations for four replicate experiments.
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mutant LI (−)
Since mutation of the VP22 dileucine motifs abrogated VP16
binding, their ability to bind to the cytoplasmic tail of gE was
examined. We utilized a modified version of the GST pulldown
assay that was described above, using the cytoplasmic tail of gE
fused to the C-terminus of GST (GST–gECT) as bait rather than
VP16. Vero cells were transfected with GFP alone or the variousVP22 dileucine motif mutants and a fraction of each cell lysate
was analyzed by Western blotting to verify that the GFP-tagged
constructs were expressed (Fig. 9A). The remaining lysates
were analyzed in the GST pulldown assay for their ability to
bind to GST–gECT, with bound material separated by SDS-
PAGE and then analyzed by Western blotting (Fig. 9B).
As we observed in a previous study, VP22 fused to the GFP
protein bound efficiently to the cytoplasmic tail of gE (O'Regan
et al., 2006). In contrast, LL (−) and LL (−)/LI (−) both failed to
Fig. 9. Characterization of the ability of VP22 dileucine motif mutants to bind to the cytoplasmic tail of gE in a GST pulldown assay. (A) Expression of VP22 dileucine
motif mutants in transfected cells. Vero cells were transfected with the indicated constructs and at 20 h post-transfection, the transfected monolayers were lysed with
NP-40 lysis buffer. A fraction of each cell lysate was analyzed for expression of the VP22–GFP fusion proteins by Western blotting using a rabbit polyclonal antibody
specific for GFP. (B) GST pulldown from transfected cell lysates using GST–gECT. The GST fusion proteins were expressed in Escherichia coli cells, purified on
glutathione-Sepharose beads, and approximately equal amounts of each were added to the remainder of the transfected cell lysates. Beads were washed extensively
with lysis buffer and bound proteins were separated by SDS-PAGE and transferred to nitrocellulose. Western blot analysis was performed using a rabbit polyclonal
antibody raised against the GFP protein. The positions of molecular mass markers (in kilodaltons) are indicated on the left. (C) Binding efficiency of VP22 dileucine
motif mutants to the cytoplasmic tail of gE. Using densitometry, binding efficiency was quantitated by dividing the amount of VP22–GFP protein detected in the
pulldown assay (normalized for the amount of GST–gECT present) by the amount in the cell lysate (normalized for the amount of actin present). In each experiment,
the wild-type VP22–GFP construct was set at 100% binding efficiency. Error bars represent standard deviations for four replicate experiments.
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the second dileucine motif in VP22 (LI) did not abrogate
interaction with gE, although binding was noticeably reduced
(approximately 33% of wild-type levels) when compared to the
VP22–GFP construct (Figs. 9B and C).
Collectively, our analysis of the VP22 dileucine motif
mutants suggests that the VP16 and gE binding activities that
map to residues 165–270 of VP22 can be separated by mutation
of the second dileucine motif to alanines. This mutation results
in a construct that fails to bind to VP16 but does retain the
ability to interact with the cytoplasmic tail of gE, albeit at
reduced levels when compared to wild-type VP22.
Virion incorporation of VP22 dileucine motif mutants
With the identification of a VP22 mutant that fails to bind
VP16, we set out to determine the contribution of VP16 bindingto VP22's incorporation into virions. To determine this we
utilized the transfection/infection-based packaging assay
described above. Analysis of the expression of the various
VP22–GFP constructs within the transfected/infected cells
showed that the dileucine motif mutants were expressed at
levels similar to wild type VP22 and migrated at the expected
molecular weight (Fig. 10A). With regard to packaging, wild-
type VP22–GFP was incorporated into virus particles, whereas
GFP alone was undetectable, despite high expression in the
transfected/infected cells (Figs. 10B and C). Mutation of the LL
dileucine motif of VP22 alone [VP22.LL (−)], or in combination
with the LI motif [VP22.LL (−)/LI (−)] resulted in constructs
that failed to be incorporated to any significant level (Figs. 10B
and C). However, the VP22.LI (−) construct (which interacts
with gE but fails to bind to VP16), was incorporated into virus
particles albeit at levels below wild-type VP22 fused to GFP
(approximately 33%). This reduced level of packaging may be a
Fig. 10. Virion incorporation of VP22 dileucine motif mutants. Expression of VP22 dileucine motif mutants in transfected/infected cells (A) and their incorporation
into virus particles (B) were analyzed as described in the legend to Fig. 6. The positions of molecular mass markers (in kilodaltons) are indicated on the left. (C)
Packaging efficiency was calculated as described in the legend to Fig. 6C. Error bars represent standard deviations for four replicate experiments.
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cytoplasmic tail of gE (Figs. 9B and C). Collectively, these
results suggest that VP16 binding is not required for incorpora-
tion of VP22 into assembling virus particles, and that the
determinant contained within residues 165–270 that facilitates
VP22 incorporation, may in fact be the gE binding activity.
Discussion
The pathway of herpesvirus tegument assembly is poorly
defined. It is not clear in which compartments(s) of the cell the
virus acquires its tegument proteins, and the mechanism by
which tegument proteins are selectively packaged into the
assembling virion remains poorly understood. It is likely that a
myriad of protein–protein interactions between capsid proteins
and tegument proteins, tegument proteins and tegument proteins
or between tegument proteins and the cytoplasmic tails of
virally encoded glycoproteins facilitate the process. The HSV-1tegument protein VP22 is packaged into virions during final
envelopment as nucleocapsids bud into TGN-derived vesicles
(Miranda-Saksena et al., 2002). This observation suggests that
interaction between VP22 and viral proteins on the cytoplasmic
face of the TGN vesicle, perhaps in concert with binding to
tegument proteins located on the surface of the approaching
capsid, ensures the accrual of VP22 in the tegument of the
assembling particle. In support of this model, VP22 is known to
associate with membranes and bind to the cytoplasmic tails of
both gD and gE (Brignati et al., 2003; Chi et al., 2005; O'Regan
et al., 2006). PrV VP22 harbors a region homologous to the gE
binding domain of HSV-1 VP22 that facilitates the interaction
of VP22 with the cytoplasmic tails of gE and gM, and VP22
fails to be incorporated into virions which do not express both
glycoproteins (Fuchs et al., 2002). VP22 also binds to VP16, an
abundant tegument protein that has been crosslinked to the
cytoplasmic tails of gB, gD and gH (Zhu and Courtney, 1994)
and has been shown to bind to the cytoplasmic tail of gH (Gross
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prior to final envelopment and its presence on the surface of
capsids undergoing secondary envelopment may facilitate
VP22's incorporation into the tegument (Miranda-Saksena et
al., 2002).
In a previous study we demonstrated that the gE binding
domain of VP22 (residues 165–270) can compete efficiently
with wild-type VP22 for packaging into assembling virions
(O'Regan et al., 2006). A recent study suggested that a similar
domain of VP22 may facilitate binding to VP16, and reported a
correlation between VP22's incorporation into virus particles
and VP16 binding (Hafezi et al., 2005). The goal of the present
study was to clarify the role VP16 binding plays in the
incorporation of VP22 and further elucidate the mechanism by
which this tegument protein is packaged.
Using a variety of N-terminal and C-terminal truncation
mutants of VP22 in both GST pulldown assays and coimmu-
noprecipitation studies, we have identified the minimal domain
of VP22 that facilitates interaction with VP16. A region
encompassing amino acids 165–225 is both necessary and
sufficient to bind to VP16 when expressed in the absence of
additional viral proteins, however such binding is only 30% of
that seen with the wild-type construct. Upon extension of this
domain to include residues 165–270, VP16 binding was
enhanced to levels greater than those observed with wild-type
VP22. This region of VP22 is highly conserved across the
herpesviruses and the conservation of sequence may indicate a
conservation of structure. Thus, the enhanced binding to VP16
may be due to a more overt exposure of the binding interface
than the wild-type VP22 construct presents. Our mapping
studies confirm and extend those from a previous study which
indicated that the VP16 binding domain of VP22 may be
located between residues 160 and 212 (Hafezi et al., 2005).
To elucidate the role VP16 binding may play in the
incorporation of VP22, we proceeded to evaluate the two
domains (165–225 and 165–270) in our transfection/infection-
based virion incorporation assay. The domain that facilitates
binding to both VP16 and the cytoplasmic tail of gE (165–270)
was packaged at levels approaching wild-type VP22 (∼54%).
This region of VP22 binds to VP16 at levels greater than the
wild-type construct, but binding to gE occurs at levels
approximately 80% of wild-type (unpublished data). Thus the
reduced level of incorporation demonstrated by this mutant
may be due to the decreased efficiency of gE binding. Residues
165–225 (which bind to VP16 but not gE) were not packaged
to any significant level suggesting, in agreement with previous
studies, that VP16 binding may not be sufficient to facilitate
VP22's incorporation (Hafezi et al., 2005; O'Regan et al.,
2006).
Both of these domains of VP22 associate with cellular
membranes, with VP22.165–225 exhibiting a higher level of
membrane association than either residues 165–270 of VP22
or the wild-type construct. In light of the incorporation data,
these results suggest that the ability to associate with cellular
membranes is not sufficient to facilitate virion incorporation
and that additional protein–protein interactions (VP16 bind-
ing, at least to wild-type levels, and gE binding) may beimportant determinants for the incorporation of VP22 into
virions.
When the virion incorporation experiments were repeated
using wild-type HSV-1 rather than a VP22-null virus to infect,
despite the mutant constructs differential binding to wild-type
VP22, the relative levels of incorporation remained the same.
Thus it would appear that full-length VP22 does not facilitate
incorporation of the truncated VP22 constructs into the virus
particle, perhaps signifying that multimerization does not play a
key role in the incorporation of VP22 into the tegument region
of assembling virus particles.
Curiously, upon deletion of residues 165–270 of VP22, the
resulting mutant was packaged into virus particles at extremely
low (approximately 8% of wild-type VP22) but reproducible
levels. It has been suggested that the C-terminus may contain a
packaging determinant of VP22 (personal communication from
Dr. John Blaho, Mount Sinai School of Medicine, New York)
(Hafezi et al., 2005). Such a packaging signal may represent the
domain of VP22 that facilitates interaction with the cytoplasmic
tail of gD (Chi et al., 2005). Perhaps this signal is contained
within VP22.Δ165–270 and may account for the low levels of
incorporation seen with this mutant.
Previous studies on the virion packaging determinants of
VP22 indicated that only VP22 constructs capable of binding to
VP16 were packaged to significant levels (Hafezi et al., 2005).
Using site-directed point mutagenesis of potential protein–
protein interaction motifs, we were able to separate the VP16
and gE binding activities within VP22. Despite abrogation of
VP16 binding with the construct VP22.LI (−), packaging into
assembling virus particles still occurred, albeit at reduced levels.
It is unclear whether the observed reduction is a result of the
inability of the LI (−) mutant to bind to VP16 or is due to the
decreased gE binding efficiency that occurs upon mutation of
this motif. Nevertheless these results indicate that VP16 binding
is not necessary for the incorporation of VP22.
While the correlation between sub-optimal packaging and
inefficient binding to the cytoplasmic tail of gE suggests an
important role for gE binding in the incorporation of VP22, one
cannot rule out the contribution that other activities of VP22
may play in the process. VP22 associates directly with cellular
membranes and is also believed to possess the ability to
multimerize (Brignati et al., 2003; Mouzakitis et al., 2005). We
have demonstrated that amino acids 165 to 270 of VP22
associate with cellular membranes in the absence of additional
viral proteins and based upon the mapping of the multi-
merization domains of VP22 by Mouzakitis et al. (2005), this
region (165–270) should possess the ability to multimerize.
Recent results from our laboratory indicate that VP22.165–270
can bind to an HA-tagged wild-type VP22 construct in the
absence of additional viral proteins (data not shown). Thus to
attain levels of incorporation greater than those observed with
VP22.165–270, it may be necessary to define a domain of VP22
that can bind to both gE and VP16 at wild-type levels.
These two binding activities may in fact act in a redundant
fashion to facilitate VP22's incorporation, perhaps in conjunc-
tion with the unidentified activity located in the C-terminal
region of the protein (gD binding?). Functional redundancy, at
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herpes virology. In HSV-1, deletion of gD or gE has little effect
on assembly, however simultaneous deletion of these glyco-
proteins results in the accumulation of unenveloped capsids in
the cytoplasm (Farnsworth et al., 2003). Similarly, the con-
current deletion of PrV's gE and gM causes the formation of
capsid-bound tegument aggregates in the cytoplasm, whereas
deletion of either glycoprotein individually has little effect
(Brack et al., 1999, 2000; Fuchs et al., 2002). As VP22 binds to
both gD and gE in HSV-1, and to gE and gM in PrV, in addition
to its VP16 binding, VP22 may act as a bridging protein, with
both VP16 and a glycoprotein tail binding simultaneously (Chi
et al., 2005; Fuchs et al., 2002; O'Regan et al., 2006). These
interactions may facilitate the budding of VP16-coated capsids
into glycoprotein/tegument protein layered vesicles. However,
recent studies of a HSV-1 VP22 null virus suggests that the
requirement for VP22 in the assembly pathway can be bypassed
(Duffy et al., 2006; Elliott et al., 2005). Thus, this may be only
one of a plethora of protein–protein interaction networks that
work redundantly to facilitate the final stages of envelopment.
Perhaps the incorporation determinants of VP22 are but another
example of the redundancy inherent to the process.
Identification of a domain harboring the ability to direct
molecules into the tegument could represent a useful vector in
the field of drug discovery and may allow the targeting of
factors with the ability to disrupt HSV-1 assembly. Studies are
in progress to assess the role of gE in VP22's incorporation and
to identify the minimal activities of VP22 required to achieve
wild-type levels of incorporation.
Materials and methods
Cells and viruses
Vero cells (ATCC CCL-81) were grown in Dulbecco's
modified Eagles medium (DMEM) (GIBCO) supplemented
with 10% fetal bovine serum (FBS), 2.25% sodium bicarbonate,
25 mM HEPES buffer, glutamine (300 μg/ml), penicillin
(100 μg/ml), and streptomycin (131 μg/ml). Infected cells were
grown in DMEM supplemented with 2% FBS, 25 mM HEPES
buffer, glutamine (300 μg/ml), penicillin (100 μg/ml), and
streptomycin (131 μg/ml). The viruses used in this study were
the KOS strain (Smith, 1964) and a VP22-null virus (UL49
−), a
kind gift from Joel Baines [Cornell University, Ithaca, New
York] (Duffy et al., 2006).
Construction and purification of GST fusion proteins
The vector encoding the cytoplasmic tail of gE fused to GST
(GST–gECT) was a kind gift from David Johnson (The Oregon
Health and Science University, Portland, Oregon).
The UL48 gene was PCR amplified by using Platinum Taq
polymerase (Invitrogen) from the HSV-1 KOS viral genome. To
construct the vector encoding GST-VP16, PCR was performed
with a forward primer containing a EcoRI site inserted
immediately upstream of the UL48 start codon and a reverse
primer that contains a NotI site immediately downstream of theUL48 stop codon. Following amplification, the VP16-encoding
DNAwas digested with EcoRI and NotI and ligated into pGEX-
4T-3 (Amersham Biosciences) digested with the same restric-
tion enzymes, to produce pGST-VP16.
The UL49 gene was PCR amplified by using Platinum Taq
polymerase (Invitrogen) from the plasmid pVP22–GFP, which
encodes a VP22–GFP fusion whose construction was described
previously (Brignati et al., 2003). To construct the vector
encoding GST–VP22, PCR was performed with a forward
primer containing a BamHI site inserted immediately upstream
of the UL49 start codon and a reverse primer that contains a
mutation to reinsert the UL49 stop codon and a NotI site
immediately downstream of the regenerated stop codon.
Following amplification, the VP22-encoding DNA was
digested with BamHI and NotI and ligated into pGEX-4T-3
(Amersham Biosciences) digested with the same restriction
enzymes, to produce pGST-VP22.
GST–VP22 N-terminal truncation mutants were made in
similar fashion. A forward primer containing an EcoRI site
upstream of the site of the truncation and the same reverse
primer used in the construction of pGST–VP22 were used to
PCR amplify the truncated UL49 gene. This product was
digested with EcoRI and NotI and ligated into the pGEX-4T-3
vector digested with the same restriction enzymes, to produce
pGST–VP22.AA-301, where “AA” designates the first amino
acid of VP22 encoded by the mutant.
GST–VP22 C-terminal truncation mutants were constructed
by using a forward primer containing an EcoRI site upstream of
the UL49 start codon and a reverse primer containing a stop
codon followed by a NotI site immediately downstream of the
site of truncation. This PCR product was digested with EcoRI
and NotI and ligated into the pGEX-4T-3 vector digested with
the same restriction enzymes, to produce pGST–VP22.1-AA,
where “AA” designates the last amino acid encoded by the
mutant.
To construct pGST–VP22.Δ87–120, the QuikChange XL
Site-Directed Mutagenesis Kit (Stratagene) was used according
to the manufacturer's instructions. Using pGST-VP22 as a
template, mutagenic primers were designed complementary to
15-bp immediately upstream of codon 87 and 15-bp immedi-
ately downstream of codon 120, essentially looping out the
sequence encoding amino acids 87–120 of VP22 in pGST–
VP22; thereby creating pVP22.Δ87–120.
To construct pGST–VP22.Δ165–225, pVP22.Δ165–225–
GFP was used as the source of the UL49 allele (described
previously; O'Regan et al., 2006). The forward primer used to
create the GST–VP22 C-terminal truncation mutants (contain-
ing an EcoRI site upstream of the UL49 start codon), and the
reverse primer used in the construction of pGST–VP22
(containing a mutation to reinsert the UL49 stop codon and
also a NotI site immediately downstream of the regenerated stop
codon) were used to PCR amplify the internally-deleted gene.
This product was digested with EcoRI and NotI and ligated into
the multiple cloning site (MCS) of pGEX-4T-3 to produce
pGST–VP22.Δ165–225.
pGST–VP22.165–225 was constructed using pVP22–GFP
as the template. The UL49 gene fragment was PCR amplified
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upstream of the codon for amino acid 165 of VP22 and a reverse
primer containing a stop codon followed by a NotI site
immediately downstream of the codon for residue 225 of
VP22. This product was digested with EcoRI and NotI and
ligated into the pGEX-4T-3 vector digested with the same
restriction enzymes, to produce pGST–VP22.165–225. All
constructs were sequenced to confirm the identity of VP16,
VP22 or the various mutant forms and to confirm that the start
codons were in frame with the gene encoding the GST protein.
To express and purify the various GST fusion proteins,
plasmids encoding the respective constructs were transformed
into BL21 competent cells (Stratagene) according to the
manufacturer's instructions and overnight cultures were
grown. Approximately 10 ml of these cultures were used to
inoculate fresh 100 ml cultures and grown at 37 °C to
A600=0.4. To induce expression, 100 μl of 1 M IPTG (GIBCO)
was added and the cultures were grown at 30 °C for 3–4 h,
followed by centrifugation at 10,000×g for 10 min at 4 °C. The
bacterial pellet was resuspended in 10 ml of lysis buffer
(100 mM Tris–HCl [pH 8.0], 1 mM EDTA, 1 mM CHAPS,
400 mM NaCl, 1% Triton X-100, Complete Mini protease
inhibitors [Roche]). The suspension was sonicated and clarified
by centrifugation at 27,000×g for 10 min at 4 °C. A volume of
133 μl of glutathione-Sepharose 4B beads (Pharmacia) that had
been washed twice with phosphate-buffered saline (PBS) was
added to the supernatant and incubated overnight at 4 °C.
Beads were washed thoroughly with PBS and the yield of each
purified GST fusion protein was determined by SDS-PAGE and
subsequent staining with Coomassie blue to detect the recom-
binant protein.
Construction of VP22–GFP chimeras
Plasmids encoding VP22 fused to GFP, the N-terminal and
C-terminal truncations of VP22 fused to GFP and the internal
truncations of VP22 (pVP22.Δ165–225–GFP, pVP22.Δ165–
270–GFP, pVP22.165–225–GFP and pVP22.165–270–GFP)
were described previously (Brignati et al., 2003; O'Regan et al.,
2006).
To make pVP22.LL(−)–GFP, the QuikChange XL Site-
Directed Mutagenesis Kit (Stratagene) was used according to
the manufacturer's instructions. Using pVP22–GFP as a
template, mutagenic primers were designed which change the
nucleotide sequence at codons 235 and 236 of VP22 to encode
for two alanine residues rather than two leucines; thereby
creating pVP22.LL(−)–GFP. A similar strategy was used to
create pVP22.LI(−)–GFP and pVP22.LL(−)/LI(−)–GFP.
All constructs were sequenced to confirm the identity of
VP22 and to ensure that the gene encoding VP22 (or the
mutated forms) was in frame with the gene encoding the GFP
protein.
GST pulldown assay
GST fusion proteins were purified from bacterial cultures, as
described above. Confluent monolayers of Vero cells grown in60-mm plates were either infected or mock infected with the
HSV-1 KOS strain at a multiplicity of infection (MOI) of 10. At
10 h post-infection, cells were washed twice with PBS and lysed
with NP-40 lysis buffer (0.5% NP-40, 150 mM NaCl, 50 mM
Tris–HCl [pH 8.0]) containing Complete Mini protease
inhibitors. Infected cell lysates were precleared overnight at
4 °C with glutathione-Sepharose 4B beads that had been
previously washed twice with PBS, and the samples were then
incubated with approximately equal amounts of purified GST-
fusion proteins on glutathione-Sepharose beads (as determined
by Coomassie blue-stained gel) for 3 h at 4 °C. Beads were
washed three times with NP-40 lysis buffer and once with
10 mM Tris–HCl (pH 7.4). VP16 bound to the GST constructs
was detected by Western blotting using a rabbit monospecific
polyclonal antibody raised against the HSV-1 tegument protein
VP16 (Clontech), a goat anti-rabbit antibody conjugated to
horseradish peroxidase (Sigma), ECL reagents (Pharmacia), and
autoradiography on Kodak BioMax XAR film. To further
control for the quantities of GST-fusion proteins used in the
pulldown, nitrocellulose membranes were stripped (60 mM
Tris–HCl [pH 8.0], 2% SDS, 0.75% β-mercaptoethanol
[β-ME] for 45 min at 55 °C) and reprobed with a goat
polyclonal antibody raised against the GST protein (Rockland).
To analyze the VP22–gE and the VP22–VP16 interaction
within transfected cells, a similar GST pulldown assay was
used. Confluent monolayers of Vero cells grown in 100-mm
plates were transfected with the indicated constructs by using
Lipofectamine 2000 (Invitrogen), according to the manufac-
turer's instructions. At 20 h post-transfection, the monolayers
were washed twice with PBS and scraped into 10 ml of cold
PBS. A 1 ml sample of the cell suspension was removed for
analysis of expression of the VP22–GFP fusion proteins, and
the remaining cells were pelleted by centrifugation (1000×g for
5 min at 4 °C). The 9 ml samples were lysed in NP-40 lysis
buffer and processed as described above. VP22–GFP fusion
proteins bound to the GST constructs were detected by Western
blotting using a rabbit polyclonal antibody raised against the
GFP protein (Santa Cruz), a goat anti-rabbit antibody
conjugated to horseradish peroxidase (Sigma), ECL reagents
(Pharmacia), and autoradiography on Kodak BioMax XAR
film. To further control for the quantities of GST-fusion proteins
used in the pulldown, nitrocellulose membranes were stripped
as described above and reprobed with a goat polyclonal
antibody raised against the GST protein (Rockland). To detect
the expression of the VP22–GFP fusion proteins in the
transfected cells, proteins in the 1 ml cell suspension sample
were analyzed by Western blotting using a rabbit polyclonal
antibody against GFP, a goat anti-rabbit antibody conjugated to
horseradish peroxidase, ECL reagents, and autoradiography on
Kodak BioMax XAR film. To ensure equal loading, nitrocellu-
lose membranes were stripped as described above and reprobed
with a goat polyclonal antibody raised against actin (Santa
Cruz). Using densitometry, binding efficiency was quantitated
by dividing the amount of VP22–GFP protein detected in the
pulldown assay (normalized for the amount of GST–VP16 or
GST-gECT present) by the amount in the cell lysate (normalized
for the amount of actin present).
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Confluent monolayers of Vero cells grown in 100-mm plates
were transfected with the indicated constructs by using
Lipofectamine 2000 (Invitrogen), according to the manufac-
turer's instructions. At 20 h post-transfection, the transfected
monolayers were infected with HSV-1 KOS strain at a MOI of
10. At 10 h post-infection (30 h post-transfection), cells were
washed twice with PBS and scraped into 10 ml of cold PBS. A
1 ml sample of the cell suspension was removed for analysis of
expression of the VP22–GFP fusion proteins, and the remaining
cells were pelleted by centrifugation (1000×g for 5 min at 4 °C).
The 9 ml samples were lysed in NP-40 lysis buffer containing
Complete Mini protease inhibitors as described above and
precleared overnight at 4 °C with protein G-agarose beads
(Roche) that had been washed twice in lysis buffer. The lysates
were then incubated with a goat polyclonal antibody raised
against GFP (Rockland) for 1 h at 4 °C, and immune complexes
were collected with protein G-agarose beads that had been
washed twice with lysis buffer. Beads were washed three times
with NP-40 lysis buffer and once with 10 mM Tris–HCl (pH
7.4). Coimmunoprecipitated VP16 was detected by Western
blotting using a rabbit monospecific polyclonal antibody raised
against a C-terminal peptide of the HSV-1 tegument protein
VP16 (Clontech), a goat anti-rabbit antibody conjugated to
horseradish peroxidase, ECL reagents, and chemiluminescence
autoradiography on Kodak BioMax XAR film. To detect the
expression of the VP22–GFP fusion proteins in the transfected/
infected cells, proteins in the 1 ml cell suspension sample were
analyzed by Western blotting using a goat polyclonal antibody
against GFP, a rabbit anti-goat antibody conjugated to horse-
radish peroxidase, ECL reagents, and autoradiography on
Kodak BioMax XAR film.
Membrane flotation assay
Confluent monolayers of Vero cells grown in 100-mm plates
were transfected with the indicated constructs by using
Lipofectamine 2000 (Invitrogen), according to the manufac-
turer's instructions. At 24 h post-transfection, the monolayers
were washed twice with PBS and scraped into 10 ml of cold
PBS. Cells were pelleted by centrifugation (1000×g for 5 min at
4 °C) and resuspended in hypotonic buffer (50 mM Tris HCl
[pH 7.4] and 3 mM MgCl2) supplemented with Protease
Inhibitor Cocktail [Sigma]. Following an incubation on ice for
15 min, the cells were lysed by 10 passsages through a 25 gauge
needle. Cell lysates were subsequently centrifuged at 1000×g
for 10 min at 4 °C to remove unbroken cells and nuclei. The
resulting supernatants were added to 85% (wt/vol) sucrose in
NTE buffer (100 mM NaCl, 10 mM Tris, 1 mM EDTA [pH
7.4]) to yield a final sucrose concentration of 72%. A
discontinuous gradient was formed by overlaying this mixture
with 65% sucrose followed by 10% sucrose. This sucrose
gradient was then centrifuged at 100,000×g for 18 h at 4 °C in a
Beckman SW41 rotor. Twelve 1 ml fractions were collected
from the bottom of the tube and trichloroacetic acid (TCA) was
added to each fraction to a final concentration of 10%. TCAprecipitation was allowed to occur overnight at 4 °C and the
resulting pellets were washed in 100% ethanol, dried and then
solubilized in 1X sample buffer (50 mM Tris–HCl [pH 6.8],
10% glycerol, 2% SDS, 5% β-ME). GFP-tagged proteins were
detected by Western blotting using a goat polyclonal antibody
raised against the GFP protein (Rockland), a rabbit anti-goat
antibody conjugated to horseradish peroxidase, ECL reagents,
and chemiluminescence autoradiography on Kodak BioMax
XAR film.
Virion incorporation assay
Confluent monolayers of Vero cells grown in 100-mm plates
were transfected with the indicated constructs using Lipofecta-
mine 2000 (Invitrogen), according to the manufacturer's
instructions. At 20 h post-transfection, cells were infected with
either HSV-1 KOS or a VP22-null virus (UL49
−) at a MOI of 10,
or mock infected. At 18 h post-infection (38 h post-transfection),
the medium was removed by pipetting and centrifuged at
1000×g for 10 min at 4 °C to remove cellular debris. The
supernatant was retained and extracellular virions were purified
by centrifugation (115,000×g for 1 h in a Beckman SW41 rotor)
through a 30% (wt/vol) sucrose cushion (1.7 ml) in NTE buffer
(100 mM NaCl, 10 mM Tris, 1 mM EDTA, [pH 7.4]). Pelleted
virions and the infected cells were disrupted in 1X sample buffer
(50 mMTris–HCl [pH 6.8], 10% glycerol, 2% SDS, 5% β-ME).
GFP-tagged proteins were detected by Western blotting using a
goat polyclonal antibody raised against the GFP protein
(Rockland), a rabbit anti-goat antibody conjugated to horse-
radish peroxidase, ECL reagents, and chemiluminescence
autoradiography on Kodak BioMax XAR film. As a loading
control, nitrocellulose membranes were stripped as described
above and reprobed with a rabbit polyclonal antibody raised
against the major capsid protein VP5. Using densitometry,
packaging efficiency was quantitated by dividing the amount of
VP22–GFP protein detected in extracellular virus particles by
the amount in the cell lysate (both normalized for VP5).
Confocal microscopy
Vero cells were transfected with the indicated constructs
using Lipofectamine 2000 (Invitrogen), according to the
manufacturer's instructions. At 20 h post-transfection, cells
were infected with HSV-1 KOS strain at a MOI of 10 or mock
infected. At 18 h post-infection (38 h post-transfection), cells
were washed twice in Tris-buffered saline (TBS), fixed with 3%
paraformaldehyde in PBS and mounted on slides using
SlowFade antifade reagent with DAPI (Molecular Probes).
Intrinsic fluorescence was observed with a Leica TSC SP2
AOBS confocal microscope using the appropriate wavelength
to excite GFP and DAPI. Images were formatted in Adobe
Photoshop 7.0.
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